Thalamic 123I FP-CIT uptake in a patient with clinical diagnosis of Parkinson's disease and depression

Hellenic Journal of Nuclear Medicine

Volumn 15, Issue 1, 2012, Pages

  Schillaci, Orazio ^a,b   Chiaravalloti, Agostino ^a   Di Pietro, Barbara ^a   Stefani, Alessandro ^c,d  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b IRCCS NEUROMED   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE PLUS PERPHENAZINE; CONTRAST MEDIUM; IODINE 123; IODINE 123 [2 BETA CARBOMETHOXY 3BETA (4 ODOPHENYL) N (3 FLUOROPROPYL)NORTROPANE]; LEVODOPA; TETROFOSMIN TC 99M; UNCLASSIFIED DRUG; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TROPANE DERIVATIVE;

AGED; BODY EQUILIBRIUM; BRADYKINESIA; BRAIN CORTEX; BRAIN MAPPING; BRAIN SCINTIANGIOGRAPHY; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DISEASE COURSE; DRUG BINDING; DRUG EFFICACY; DRUG UPTAKE; DRUG WITHDRAWAL; HUMAN; HYPERREFLEXIA; LETTER; MALE; MENTAL DISEASE; MESENCEPHALON; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RIGIDITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATE CORTEX; THALAMUS; TROCHLEAR NERVE; TROCHLEAR NERVE DISEASE; UNIFIED PARKINSON DISEASE RATING SCALE; METABOLISM; SCINTISCANNING;

AGED; DEPRESSION; HUMANS; MALE; PARKINSON DISEASE; RADIOPHARMACEUTICALS; THALAMUS; TROPANES;

EID: 84859197927     PISSN: 11081430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (17)

1. Hornykiewicz O. Dopamine and brain function. Pharmacol Rev 1966; 18: 925-64.
2. Marsden CD. Parkinson's disease, Lancet 1990; 335: 948-52. (Pubitemid 20134975)
3. Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement Disorders. London, U.K.: Butterworth; 1987: 166-230.
4. Halliday GM, Blumberg PC, Cotton RG et al. Loss of brain stem serotonin and substance P-containing neurons in Parkinson's disease. Brain Res 1990; 510: 104-7. (Pubitemid 20060808)
5. Jellinger K. New developments in the pathology of Parkinson's disease. Adv Neurol 1990; 53: 116.
6. Scatton B, Javoy-Agid F, Rouquier L et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983; 275: 321-8. (Pubitemid 13004530)
7. 3H-imipramine binding sites in control and parkinsonian brains. Eur J Pharmacol 1985; 117: 71-80.
8. Raisman R, Cash R, Agid Y. Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen. Neurology 1986; 36: 556-60. (Pubitemid 16070015)
9. 123I-β-CIT. Eur J Pharmacol 1991; 200: 369-70.
10. 125I-RT1-55: potent ligand for dopamine transporters. Eur J Pharmacol 1991: 194: 133-4.
11. 125I-2β- carbomethoxy-3-β-(iodophenyl)-tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in the brain. Med Chem 1991: 34: 314-46.
12. 123I-FP-CIT SPECT in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997; 24: 68-71.
13. 123I-β-CIT SPECT study. J Neural Transm 2008; 115: 721-9.
14. 123I-FP-CIT SPECT. Mov Disord 2010; 25(12): 1853-9.
15. 123I beta-CIT SPECT. J Nuc Med 2003; 44(6): 870-6.
16. Hesse S, Meyer P, Stecker K et al. Monoamine transporter availability in Parkinson's disease patients with or without depression. Eur J Nucl Med Mol Imag 2009; 36: 428-35.
17. Gordon PH, Pullman SL, Louis ED et al. Mirtazapine in Parkinsonian tremor. Park Relat Disord 2002; 9: 125-6. (Pubitemid 35447541)